Efficacy of Antiplatelet Agent Usage for Primary and Secondary Prevention in Dialysis Patients: a Nationwide Data Survey and Propensity Analysis
ConclusionsAntiplatelet agent usage does not reduce CV events and total mortality in dialysis patients.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
More News: Aspirin | Cardiology | Cardiovascular | Clopidogrel | Databases & Libraries | Dialysis | Heart | Hemodialysis | Peritoneal Dialysis | Plavix | Study | Taiwan Health